Valsartan And Hydrochlorothiazide
Product Images NDC 53002-2784

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 53002-2784). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530022784)

Label for Valsartan and Hydrochlorothiazide 80 mg / 12.5 mg tablets by RPK Pharmaceuticals, Inc. The label states the product contains 90 tablets, to be taken one tablet daily as directed. It includes prescription-only designation, lot number, expiration date, storage conditions, barcode, and placeholders for clinic and prescriber details.*

FDA Label Image

Figure-1 (Valsartan Hctz Figure 1)

A line graph showing the percentage of patients with systolic blood pressure (SBP) less than 140 mmHg. The x-axis represents baseline SBP from 140 to 180 mmHg, and the y-axis shows the percentage from 0 to 100%. Four treatment groups are shown: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with Valsartan HCT 320/25 mg showing the highest percentages across baseline SBP values.*

FDA Label Image

Figure-2 (Valsartan Hctz Figure 2)

A line graph depicting the percentage of subjects with diastolic blood pressure (DBP) less than 90 mmHg (% DBP<90) versus baseline DBP measurements (mmHg). The graph compares four groups labeled as Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by distinct markers and lines showing trends across baseline DBP values from 90 to 110 mmHg.*

FDA Label Image

Figure-3 (Valsartan Hctz Figure 3)

A line chart showing the percentage of patients achieving systolic blood pressure (SBP) under 130 mmHg across baseline SBP levels for Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo groups. The x-axis represents baseline SBP in mmHg, and the y-axis shows the percentage of patients with SBP <130 mmHg.*

FDA Label Image

Figure-4 (Valsartan Hctz Figure 4)

A line graph depicting the percentage of patients achieving diastolic blood pressure (DBP) under 80 mmHg based on baseline DBP measurements. It compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with baseline DBP on the x-axis and percentage on the y-axis.*

FDA Label Image

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)

Chemical structure of the active ingredients in Valsartan and Hydrochlorothiazide. The image shows the molecular arrangement including sulfonamide and chlorine groups typical for these compounds.*

FDA Label Image

Valsartan-str (Valsartan Hctz Valsartan)

Chemical structure diagram depicting the molecular formula of valsartan, an active ingredient of the Valsartan and Hydrochlorothiazide medication by RPK Pharmaceuticals, Inc. The diagram shows the arrangement of atoms and bonds characteristic of valsartan's chemical structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.